• Users Online: 86
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login

   Instructions to the Authors

The Editorial Process |  Clinical trial registry Authorship Criteria |  Contribution Details |  Conflicts of Interest / Competing Interests | Submission of Manuscripts | Preparation of Manuscripts | Copies of any permission(s) | Types of Manuscripts | Protection of Patients' Rights | Sending a revised manuscript | Reprints and proofs | Manuscript submission..Copyrights  Checklist Contributors' form | Browse by category


 The Editorial Process Top

A manuscript will be reviewed for possible publication with the understanding that it is being submitted to Asia Pacific Journal of Clinical Trials: Nervous System Diseases alone at that point in time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. The journal expects that authors would authorize one of them to correspond with the Journal for all matters related to the manuscript. All manuscripts received are duly acknowledged. On submission, editors review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the Asia Pacific Journal of Clinical Trials: Nervous System Diseases readers are also liable to be rejected at this stage itself.

Manuscripts that are found suitable for publication in Asia Pacific Journal of Clinical Trials: Nervous System Diseases are sent to two or more expert reviewers. During submission, the contributor is requested to provide names of two or three qualified reviewers who have had experience in the subject of the submitted manuscript, but this is not mandatory. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other’s identity. Every manuscript is also assigned to a member of the editorial team, who based on the comments from the reviewers takes a final decision on the manuscript. The comments and suggestions (acceptance/ rejection/ amendments in manuscript) received from reviewers are conveyed to the corresponding author. If required, the author is requested to provide a point by point response to reviewers’ comments and submit a revised version of the manuscript. This process is repeated till reviewers and editors are satisfied with the manuscript.

Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within three days. It may not be possible to incorporate corrections received after that period. The whole process of submission of the manuscript to final decision and sending and receiving proofs is completed online. To achieve faster and greater dissemination of knowledge and information, the journal publishes articles online as ‘Ahead of Print’ immediately on acceptance.

 Clinical trial registry   Top

Asia Pacific Journal of Clinical Trials: Nervous System Diseases favors registration of clinical trials and is a signatory to the Statement on publishing clinical trials in Indian biomedical journals. Asia Pacific Journal of Clinical Trials: Nervous System Diseases would publish clinical trials that have been registered with a clinical trial registry that allows free online access to public. Registration in the following trial registers is acceptable: http://www.ctri.in/; http://www.actr.org.au/; http://www.clinicaltrials.gov/; http://isrctn.org/; http://www.trialregister.nl/trialreg/index.asp; and http://www.umin.ac.jp/ctr. This is applicable to clinical trials that have begun enrollment of subjects in or after June 2008. Clinical trials that have commenced enrollment of subjects prior to June 2008 would be considered for publication in Asia Pacific Journal of Clinical Trials: Nervous System Diseases only if they have been registered retrospectively with clinical trial registry that allows unhindered online access to public without charging any fees.

 Authorship Criteria Top

Authorship credit should be based only on substantial contributions to each of the three components mentioned below: 

  1. Concept and design of study or acquisition of data or analysis and interpretation of data;
  2. Drafting the article or revising it critically for important intellectual content; and
  3. Final approval of the version to be published.

Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors. The journal prescribes a maximum number of authors for manuscripts depending upon the type of manuscript, its scope and number of institutions involved (vide infra). The authors should provide a justification, if the number of authors exceeds these limits.

 Contribution Details Top

Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided in following categories, as applicable: concept, design, definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review. Authors' contributions will be printed along with the article. One or more author should take responsibility for the integrity of the work as a whole from inception to published article and should be designated as 'guarantor'. 

 Conflicts of Interest/ Competing Interests Top

All authors of must disclose any and all conflicts of interest they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript.

 Submission of Manuscripts Top

All manuscripts must be submitted on-line through the website http://www.journalonweb.com/apctnsd. First time users will have to register at this site. Registration is free but mandatory. Registered authors can keep track of their articles after logging into the site using their user name and password.

The journal does not charge for submission and processing of the manuscripts.

. If you experience any problems, please contact the editorial office by e-mail at editor [AT] actnjournal . com

The submitted manuscripts that are not as per the “Instructions to Authors” would be returned to the authors for technical correction, before they undergo editorial/ peer-review. Generally, the manuscript should be submitted in the form of two separate files:

[1] Title Page/First Page File/covering letter:

This file should provide

  1. The type of manuscript (original article, case report, review article, Letter to editor, Images, etc.) title of the manuscript, running title, names of all authors/ contributors (with their highest academic degrees, designation and affiliations) and name(s) of department(s) and/ or institution(s) to which the work should be credited, . All information which can reveal your identity should be here. Use text/rtf/doc files. Do not zip the files.
  2. The total number of pages, total number of photographs and word counts separately for abstract and for the text (excluding the references, tables and abstract), word counts for introduction + discussion in case of an original article;
  3. Source(s) of support in the form of grants, equipment, drugs, or all of these;
  4. Acknowledgement, if any. One or more statements should specify 1) contributions that need acknowledging but do not justify authorship, such as general support by a departmental chair; 2) acknowledgments of technical help; and 3) acknowledgments of financial and material support, which should specify the nature of the support. This should be included in the title page of the manuscript and not in the main article file.
  5. If the manuscript was presented as part at a meeting, the organization, place, and exact date on which it was read. A full statement to the editor about all submissions and previous reports that might be regarded as redundant publication of the same or very similar work. Any such work should be referred to specifically, and referenced in the new paper. Copies of such material should be included with the submitted paper, to help the editor decide how to handle the matter.
  6. Registration number in case of a clinical trial and where it is registered (name of the registry and its URL)
  7. Conflicts of Interest of each author/ contributor. A statement of financial or other relationships that might lead to a conflict of interest, if that information is not included in the manuscript itself or in an authors' form
  8. Criteria for inclusion in the authors’/ contributors’ list
  9. A statement that the manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work, if that information is not provided in another form (see below); and
  10. The name, address, e-mail, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs, if that information is not included on the manuscript itself.

[2] Blinded Article file: The main text of the article, beginning from Abstract till References (including tables) should be in this file. The file must not contain any mention of the authors' names or initials or the institution at which the study was done or acknowledgements. Page headers/running title can include the title but not the authors' names. Manuscripts not in compliance with the Journal's blinding policy will be returned to the corresponding author. Use rtf/doc files. Do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file. The pages should be numbered consecutively, beginning with the first page of the blinded article file.

[3] Images: Submit good quality color images. Each image should be less than 2 MB in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to 1600 x 1200 pixels or 5-6 inches). Images can be submitted as jpeg files. Do not zip the files. Legends for the figures/images should be included at the end of the article file. 

[4] The contributors' / copyright transfer form (template provided below) has to be submitted in original with the signatures of all the contributors within two weeks of submission via courier, fax or email as a scanned image. Print ready hard copies of the images (one set) or digital images should be sent to the journal office at the time of submitting revised manuscript. High resolution images (up to 5 MB each) can be sent by email.

Contributors’ form / copyright transfer form can be submitted online from the authors’ area on http://www.journalonweb.com/apctnsd.

 Preparation of Manuscripts Top

Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journals" developed by the International Committee of Medical Journal Editors (October 2008). The uniform requirements and specific requirement of Asia Pacific Journal of Clinical Trials: Nervous System Diseases are summarized below. Before submitting a manuscript, contributors are requested to check for the latest instructions available. Instructions are also available from the website of the journal (http://www.actnjournal.com) and from the manuscript submission site http://www.journalonweb.com/apctnsd).

Asia Pacific Journal of Clinical Trials: Nervous System Diseases accepts manuscripts written in American English.

-All manuscript components should be typed, double-spaced, in Arial font (11 pt). All pages should be consecutively numbered, beginning with the title page, and presented in the following order: abstract, background, protocol design, discussion, conclusion, abbreviations, competing interests, author contributions, author information, acknowledgments, figure titles, figures/tables. 
Title page
-The title should be brief (fewer than 20 words, 90 characters maximum), novel, and informative. It should identify the study type, facilitate retrieval, and be without abbreviations.
-List the names, affiliations (including department, institution, city, province/state, country, postal code), and email addresses of all authors. Specify the corresponding author.
-Maximum of 350 words. Structured with the following subheadings: Background, Methods/Design, Discussion, and Trial Registration (registration database, registration identifier, and the precise date of trial registration).
-Use as few abbreviations as possible. No citations.
Key Words
-Provide 6–10 words, not present in the title, to facilitate indexing.
-Original articles should cite references that have been published within the preceding 3 years. Asia Pacific Journal of Clinical Trials: Nervous System Diseases uses the reference style of The Journal of Neuroscience. Please download this style from EndNote (http://endnote.com/downloads/style/journal-neuroscience).
-References should be cited in the text as follows: “The procedure used has been described elsewhere (Green, 1978),” or “Our observations are in agreement with those of Brown and Black (1979) and of White et al. (1980),” or with multiple references, in chronological order: “Earlier reports (Brown and Black, 1979, 1981; White et al., 1980; Smith, 1982, 1984)...”.
-In the list of references (EndNote required to view download), the titles of journals should be abbreviated according to the style used in Index Medicus. The papers should be arranged in alphabetical order by the surname of the first authors. In two-author papers with the same first author, the order is alphabetical by the second author’s name. In three- or more-author papers with the same first author, the order is chronological. If there are more than 20 authors, the first 20 should be listed, followed by et al.
-The following formats are to be used:
Journal paper
       Hamill OP, Marty A, Neher E, Sakmann B, Sigworth F (1981) Improved patch-clamp techniques for high-resolution current recordings from cells and cell free membrane patches. Pflugers Arch 391:85-100.
       Hodgkin AL, Huxley AF (1952a) The components of membrane conductance in the giant axon of Loligo. J Physiol (Lond) 116:473-496.
       Hodgkin AL, Huxley AF (1952b) The dual effect of membrane potential on sodium conductance in the giant axon of Loligo. J Physiol (Lond) 116:497-506.
In-press paper
       Mollica A, Costante R, Novellino E, Stefanucci A, Pieretti S, Zador F, Samavati R, Borsodi A, Benyhe S, Vetter I, Lewis RJ (2014) Design, synthesis and biological evaluation of two opioid agonist and Cav 2.2 blocker multi-target ligands. Chem Biol Drug Des doi: 10.1111/cbdd.12479.
       Hille B (1984) Ionic channels of excitable membranes. Sunderland, MA: Sinauer.
Chapter in a book
       Stent GS (1981) Strength and weakness of the genetic approach to the development of the nervous system. In: Studies in developmental neurobiology: essays in honor of Viktor Hamburger (Cowan WM, ed), pp288-321. New York: Oxford UP.
Figures and tables
-Each figure should be provided with a fully descriptive title and legend. The area(s) of interest must be clearly indicated with arrows or other symbols.
-Figure legends must be self-explanatory and should provide sufficient detail to be intelligible without reference to the main text.
-All micrographs should contain a magnification scale bar. Please position the scale bar in the lower-right corner of a single micrograph or of the last panel (for figures with multiple panels). The length of the scale bar should be indicated on the images or in the figure legend. The images contained in a figure should be arranged in sequence from the top left to the bottom right. The tags (A, B, C…) should be positioned in the upper-left corner of each image.
-All abbreviations and labels appearing on the image should be explained in the figure legend. If the figures have been reproduced from another source, written permission for reproducing the material must be attached to the cover letter.
-The figures should be cited consecutively in the text and numbered in that order. Each figure should be placed on a separate page following the reference list and include the figure title and legend. The figure title should not be written on the figure itself. The symbols and abbreviations in the figure legends should be written out.
-All measurements in the figure should be in SI (metric) units.
-A comma should be used to separate thousands. Labels, including *, **, ***, #, ##, and ### (in that order), should be used to identify statistically significant differences between datasets on histograms or line drawings.
-Color figure: resolution > 300 dpi; file format EPS, TIFF or PDF; CMYK mode should be used rather than RGB; use high contrasting colors for color discrimination.
-Line figures: resolution > 1,200 dpi; line width between 0.5 and 4 point; file format EPS or PDF.
-Grayscale figures: resolution > 600 dpi: file format EPS, TIFF or PDF.
-Figures should remain sharp at 300-fold magnification.
-Figures should be sized to fit within a column (9 cm) or the full-text width (18 cm).
-All labels on the figures should be in Arial or Times New Roman font and be clearly legible.

 Copies of any permission(s) Top

It is the responsibility of authors/ contributors to obtain permissions for reproducing any copyrighted material. A copy of the permission obtained must accompany the manuscript. Copies of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the manuscript must also accompany the manuscript. The material should be sent to any of the two addresses given above.

 Types of Manuscripts Top

ACTN publishes the following article types:

Study Protocol
• Research Data
• Hypotheses
• Project Management Report
• Letters

Each article type published by Trials follows a specific format, as detailed in the corresponding instructions for authors; please view the instructions for authors.

Manuscript Format and Structure
-Describe a hot topic in the research field of clinical trial protocols or clinical and translational medicine on nervous system diseases or psychiatric or psychological disorders.
-Present author’s viewpoints and the recognition and summary of this scientific process as well as future hypotheses.
-Highlight translational application of novel techniques and methods described in preclinical basic studies to clinical practice.
-Submit an outline for your manuscript before writing the article, and then submit the manuscript within 2 months of receiving permission from the Asia Pacific Journal of Clinical Trials: Nervous System Diseases editorial committee.
-Maximum of 1500–2000 words, excluding references. No abstract or tables. One figure is permitted. Translational significance of techniques or methods used is required in the concluding sentences.
-Maximum of 90 characters (20 words).
Authors and affiliations
-Maximum of 2 authors; maximum of 2 affiliations.
-Maximum of 10. Use the reference style of The Journal of Neuroscience.
-Submit an outline for your manuscript before writing the article, and then submit the manuscript within 2 months of receiving permission from the Asia Pacific Journal of Clinical Trials: Nervous System Diseases editorial committee.
-Word limit: 6,000 words maximum including the abstract, but excluding references, tables and figures.
-Title: 90 characters (20 words) maximum.

- A short, unstructured, single paragraph summary, no more than 350 words, of the major points raised, making evident the key work highlighted in the article.
Key Words
-Provide 6–10 words.
-Briefly present the nature and scope of the problem under investigation.
-Text body (several paragraphs if necessary).
-Concluding sentences and significance.
Competing interests
Author contributions
Author information

-Use the reference style of The Journal of Neuroscience.
Figures and Tables
-Descriptive title identifying the study design, population, and intervention.
- This should not exceed 350 words and should be structured into separate sections headed Background, Methods/Design, Discussion, and Trial Registration (please list the trial registry, along with the unique identifying number, e.g. Trial registration: NCT02192320.
Key Words
-Provide 6–10 words, not present in the title, representing the main content of the article.

-Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and adverse effects of each intervention.
-Explanation for set of controls.
-Specific objectives or hypotheses.

Trial Design/Methods
Design type
-Follow the guidelines of the International Headache Society Committee on Clinical Trials in Migraine.
-Description of trial design, including type of trial (e.g., parallel group, crossover, factorial, single group), allocation ratio and framework (e.g., superiority, equivalence, non-inferiority, exploratory).
-Study setting.
-Inclusion, exclusion, rejection, and withdrawal criteria for participants.
-Interventions for each group with sufficient detail to allow replication, including how and when they will be administered; criteria for discontinuing or modifying allocated interventions for a given trial participant (e.g., drug dose change in response to harm, participant request, or improving/worsening disease); strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (e.g., drug tablet return, laboratory tests); and relevant concomitant care and interventions that are permitted or prohibited during the trial.
-Primary, secondary, and other outcomes, including the specific measurement variable (e.g., systolic blood pressure), analysis metric (e.g., change from baseline, final value, time to event), method of aggregation (e.g., median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended.
Participant timeline
-Schedule of enrollment-interventions (including any run-in and washout periods), assessments, and visits for participants. A schematic diagram (figure) is highly recommended.
Study setting
-Description of study settings (e.g., community clinic, academic hospital) and list of countries where data will be collected.
Sample size
-Estimated number of participants needed to achieve study objectives and how this number was determined, including clinical and statistical assumptions supporting any sample size calculations.
-Strategies for achieving adequate participant enrollment to reach target sample size.
Assignment of interventions (for controlled trials)
Allocation sequence generation
-Method of generating the allocation sequence (e.g., computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (e.g., blocking) should be provided in a separate document that is unavailable to those who enroll participants or assign interventions.
Allocation concealment mechanism
-Mechanism of implementing the allocation sequence (e.g., central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned.
-Who will generate the allocation sequence, who will enroll participants, and who will assign participants to interventions.
Blinding (masking)
-Who will be blinded after assignment to interventions (e.g., trial participants, care providers, outcome assessors, data analysts) and how. If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial.
Data collection, management, and analysis
Data collection methods
-Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (e.g., duplicate measurements, training of assessors) and description of study instruments (e.g., questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol.
-Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols.
Data management
-Plans for data entry, coding, security, and storage, including any related processes to promote data quality (e.g., double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol.
Statistical methods
-Statistical methods for analyzing primary and secondary outcomes. Reference to where other details of the statistical analyses plan can be found, if not in the protocol.
Data monitoring
-Composition of data monitoring committee; summary of the committee’s role and reporting structure; statement of whether the committee is independent from the sponsor and competing interests.
-Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial.
-Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct.
-Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor.
Ethics and dissemination
Research ethics approval
-Plans for seeking research ethics committee/institutional review board approval.
Protocol amendments
-Plans for communicating important protocol modifications (e.g., changes to eligibility criteria, outcomes, analyses) to relevant parties (e.g., investigators, research ethics committee/institutional review committee, trial participants, trial registries, journals, regulators).
Consent or assent
-Who will obtain informed consent or assent from potential trial participants or authorized surrogates, and how will this be obtained.
-Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable.
-How personal information about potential and enrolled participants will be collected, shared, and maintained to protect confidentiality before, during, and after the trial.
Declaration of interests
-Financial and other competing interests for principal investigators for the overall trial and each study site.
Access to data
-Statement of who will have access to the final trial data set, and disclosure of contractual agreements that limits such access for investigators.
Biological specimens
-Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable.
Trial status
- The status of the trial at the time of manuscript submission. The journal considers study protocol articles for proposed or ongoing trials provided they have not completed patient recruitment at the time of submission.
- If abbreviations are used in the text they should be defined in the text at first use.
Competing interests

-After acceptance, the authors must declare potential conflicts of interest. All authors must agree with the conflict declaration in the final version of the paper.
Author contributions
-Identify the contributions of each author to the paper.
-Those who contributed to the work but do not meet the authorship criteria should be listed in this section with a description of their contribution.
ACTN has adopted the reference style of “Journal of Neuroscience”.
Figures and Tables
Author information

Note: This document was reproduced based on the SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials.   
-An in-depth analysis of an issue published in this or other journals.
-Evaluation of novel techniques, methods, and theoretical studies of concern to readers.
-Issues must meet the journal’s publishing criteria and be of interest to its readers.
-Maximum of 2,000 words, excluding references. No abstract, tables, or figures.
-Maximum of 90 characters (20 words).
Author information
-Maximum of 5. Use the reference style of The Journal of Neuroscience.

Protection of Patients' Rights to Privacy  Top

Identifying information should not be published in written descriptions, photographs, sonograms, CT scans, etc., and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian, wherever applicable) gives written informed consent for publication. Authors should remove patients' names from figures unless they have obtained written informed consent from the patients. When informed consent has been obtained, it should be indicated in the article and copy of the consent should be attached with the covering letter. 

Sending a revised manuscript  Top

The revised version of the manuscript should be submitted online in a manner similar to that used for submission of the manuscript for the first time. However, there is no need to submit the “First Page” or “Covering Letter” file while submitting a revised version. When submitting a revised manuscript, contributors are requested to include, the ‘referees’ remarks along with point to point clarification at the beginning in the revised file itself. In addition, they are expected to mark the changes as underlined or colored text in the article.

Reprints and proofs  Top

Journal provides no free printed reprints. Authors can purchase reprints, payment for which should be done at the time of submitting the proofs.

Publication schedule

The journal publishes articles on its website immediately on acceptance and follows a ‘continuous publication’ schedule. Articles are compiled for ‘print on demand’ semiannual issues.

Manuscript submission, processing and publication charges  Top

The journal does not charge for submission and processing of the manuscripts.

Copyrights   Top

The entire contents of the Asia Pacific Journal of Clinical Trials: Nervous System Diseases are protected under Indian and international copyrights. The Journal, however, grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.

Checklist   Top

Covering letter

  • Signed by all contributors
  • Previous publication / presentations mentioned
  • Source of funding mentioned
  • Conflicts of interest disclosed


  • Last name and given name provided along with Middle name initials (where applicable)
  • Author for correspondence, with e-mail address provided
  • Number of contributors restricted as per the instructions
  • Identity not revealed in paper except title page (e.g. name of the institute in Methods, citing previous study as 'our study', names on figure labels, name of institute in photographs, etc.)

Presentation and format

  • Double spacing
  • Margins 2.5 cm from all four sides
  • Page numbers included at bottom
  • Title page contains all the desired information
  • Running title provided (not more than 50 characters)
  • Abstract page contains the full title of the manuscript
  • Abstract provided (structured abstract of 250 words for original articles, unstructured abstracts of about 150 words for all other manuscripts excluding letters to the Editor)
  • Key words provided (three or more)
  • Introduction of 75-100 words
  • Headings in title case (not ALL CAPITALS)
  • The references cited in the text should be after punctuation marks, in superscript with square bracket.
  • References according to the journal's instructions, punctuation marks checked
  • Send the article file without ‘Track Changes’

Language and grammar

  • Uniformly American English
  • Write the full term for each abbreviation at its first use in the title, abstract, keywords and text separately unless it is a standard unit of measure. Numerals from 1 to 10 spelt out
  • Numerals at the beginning of the sentence spelt out
  • Check the manuscript for spelling, grammar and punctuation errors
  • If a brand name is cited, supply the manufacturer's name and address (city and state/country).
  • Species names should be in italics

Tables and figures

  • No repetition of data in tables and graphs and in text
  • Actual numbers from which graphs drawn, provided
  • Figures necessary and of good quality (colour)
  • Table and figure numbers in Arabic letters (not Roman)
  • Labels pasted on back of the photographs (no names written)
  • Figure legends provided (not more than 40 words)
  • Patients' privacy maintained (if not permission taken)
  • Credit note for borrowed figures/tables provided
  • Write the full term for each abbreviation used in the table as a footnote
Contributors' form  Top

(to be modified as applicable and one signed copy attached with the manuscript)

Manuscript Title:

I/we certify that I/we have participated sufficiently in contributing to the intellectual content, concept and design of this work or the analysis and interpretation of the data (when applicable), as well as writing of the manuscript, to take public responsibility for it and have agreed to have my/our name listed as a contributor.

 I/we believe that the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under my/our authorship has been published or is being considered for publication elsewhere, except as described in the covering letter. I/we certify that all the data collected during the study is presented in this manuscript and no data from the study has been or will be published separately. I/we attest that, if requested by the editors, I/we will provide the data/information or will cooperate fully in obtaining and providing the data/information on which the manuscript is based, for examination by the editors or their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in the cover letter. Sources of outside support of the project are named in the covering letter. 

I/We hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership, including any and all rights incidental thereto, exclusively to the Asia Pacific Journal of Clinical Trials: Nervous System Diseases, in the event that such work is published by the Asia Pacific Journal of Clinical Trials: Nervous System Diseases. The Asia Pacific Journal of Clinical Trials: Nervous System Diseases shall own the work, including

  1. copyright;
  2. the right to grant permission to republish the article in whole or in part, with or without fee;
  3. the right to produce preprints or reprints and translate into languages other than English for sale or free distribution; and
  4. the right to republish the work in a collection of articles in any other mechanical or electronic format.

We give the rights to the corresponding author to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and he/she will act as the guarantor for the manuscript on our behalf.

All persons who have made substantial contributions to the work reported in the manuscript, but who are not contributors, are named in the Acknowledgment and have given me/us their written permission to be named. If I/we do not include an Acknowledgment that means I/we have not received substantial contributions from non-contributors and no contributor has been omitted.

Name Signature Date signed
1 --------------- --------------- ---------------
2 --------------- --------------- ---------------
3 --------------- --------------- ---------------
4 --------------- --------------- --------------- (up to 4 contributors for case report/ images/ review)
5 --------------- --------------- ---------------
6 --------------- --------------- --------------- (up to 6 contributors for original studies)

Click here to download instructions

Click here to download copyright form


These ready to use templates are made to help the contributors write as per the requirements of the Journal.

Save the templates on your computer and use them with a word processor program. 
Click open the file and save as the manuscript file.

In the program keep 'Document Map' and 'Comments' on from 'View' menu to navigate through the file. 

Download Template for Original Articles/ABSTRACT Reports. (.DOT file)

Download Template for Case Reports.  (.DOT file)

Download Template for Review Articles.  (.DOT file)

Download Template for Letter to the Editor.  (.DOT file)

Browse by category Top

Please visit http://www.stm-pub.com/CN/model/lanmu1.shtml to view article collections.



What's New
Reference style (PPS)
Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal